A similar concept was applied by combining a mesothelin CAR and a Folate receptor CCR to target ovarian cancer or combining a CD13 CAR and a TIM3 CCR to target acute myeloid leukemia (AML). Here, MSLN is linked to acute myeloid leukemia.